Qilu Pharmaceutical Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
A Study of QL1706H in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06047431
A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT06041035
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Study of QLF3108 in Participants With Advanced Solid Tumor
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT06019013
- Locations
- 🇨🇳
Chinese People's Liberation Army (PLA) General Hospital, Beijing, Beijing, China
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 668
- Registration Number
- NCT05976568
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, China
Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05973149
- Locations
- 🇨🇳
Department of Urology, Peking University First Hospital, Beijing, Beijign, China
🇨🇳Department of Urology, Drum Tower Hospital, Nanjing University School of Medicine, Nanjing, Jiangsu, China
Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 478
- Registration Number
- NCT05950516
- Locations
- 🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China
Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05932888
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05920876
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT05884801
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers
- Conditions
- Neoplasms
- Interventions
- Drug: The test olaparib tablet (T)Drug: The reference olaparib tablet (R)
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05860530
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China